European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB)
The European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB) project started on 1 December 2023 and is scheduled to run until 30 November 2024. A total of 499,210 euros is available for the project. The STERN BioRegion will receive 59,820 euros, of which 100 per cent will be funded.
EHAB Mission
EHAB’s mission is to identify regional strengths, weaknesses, gaps and needs in a consolidated transregional Advanced Therapies and Biomaterials (AT&B) value chain and to elaborate a joint action plan to strengthen the performance and capacity of the innovation ecosystems of e.g. SME’s innovation stakeholders and their efficient interconnections ant their alignment towards EU-level priorities, jointly tackling challenges at EU, national, regional, and local level together with all the quadruple helix stakeholders.
Participants EHAB
- Brabant Development Agency (BOM), The Netherlands)
- Brightlands Biomedical Ecosystem represented by Brightlands Maastricht Health Campus, The Netherlands
- FlandersBio, Belgium
- BioRegio STERN, Germany
- A4tec-association (A4TEC), Portugal
- BIOCAT, Spain
- Resarch Institutes of Sweden AB (RISE), Sweden
- MedSilesia, Gornslaski Akcelerator Przedsiebiorczosci Rynkowej sp z o.o. (GAPR), Poland
EHAB is endorsed by several regional and European level organisations, including : the Province of North-Brabant, the Province of Limburg, the RegMed XB consortium, the department of Economy, Science and Innovation of the Flemish Government, the Smart Health Pilot of the Vanguard Initiative, the Health Department from the Generalitat de Catalunya, Leitat, ASEBIO, the Vall d’Hebron Institute of Oncology, the Fraunhofer-Institut für Produktionstechnik und Automatisierung (Fraunhofer IPA), and the Marshall Office of the Silesia Voivodeship.